182 related articles for article (PubMed ID: 35171534)
41. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial.
von Einem JC; Heinemann V; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Decker T; Klein S; Held S; Jung A; Kirchner T; Haas M; Holch J; Michl M; Aubele P; Boeck S; Schulz C; Giessen C; Stintzing S; Modest DP
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1607-14. PubMed ID: 24816724
[TBL] [Abstract][Full Text] [Related]
42. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
[TBL] [Abstract][Full Text] [Related]
43. The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status: A Study By the International Genetic Consortium for Colorectal Liver Metastasis.
Margonis GA; Amini N; Buettner S; Kim Y; Wang J; Andreatos N; Wagner D; Sasaki K; Beer A; Kamphues C; Morioka D; Løes IM; Imai K; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Burkhart R; Endo I; Baba H; Mischinger HJ; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
Ann Surg; 2021 Jun; 273(6):1165-1172. PubMed ID: 31389831
[TBL] [Abstract][Full Text] [Related]
44. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
45. Assessing the Impact of Primary Tumour Location on Survival After Resection of Colorectal Liver Metastases: A Propensity Weighted Retrospective Cohort Study.
Borakati A; Froghi F; Shetye A; Fusai GK; Davidson BR; Mirnezami R
World J Surg; 2022 Jul; 46(7):1734-1755. PubMed ID: 35325347
[TBL] [Abstract][Full Text] [Related]
46. Impact of BRAF mutations on clinical outcomes following liver surgery for colorectal liver metastases: An updated meta-analysis.
Gau L; Ribeiro M; Pereira B; Poirot K; Dupré A; Pezet D; Gagnière J
Eur J Surg Oncol; 2021 Nov; 47(11):2722-2733. PubMed ID: 34099355
[TBL] [Abstract][Full Text] [Related]
47. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.
Karagkounis G; Torbenson MS; Daniel HD; Azad NS; Diaz LA; Donehower RC; Hirose K; Ahuja N; Pawlik TM; Choti MA
Cancer; 2013 Dec; 119(23):4137-44. PubMed ID: 24104864
[TBL] [Abstract][Full Text] [Related]
48. RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases.
Okuno M; Goumard C; Kopetz S; Vega EA; Joechle K; Mizuno T; Omichi K; Tzeng CD; Chun YS; Vauthey JN; Conrad C
Ann Surg Oncol; 2018 Aug; 25(8):2457-2466. PubMed ID: 29786130
[TBL] [Abstract][Full Text] [Related]
49. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.
Siyar Ekinci A; Demirci U; Cakmak Oksuzoglu B; Ozturk A; Esbah O; Ozatli T; Celik B; Budakoglu B; Turker I; Bal O; Turan N
J BUON; 2015; 20(1):128-35. PubMed ID: 25778307
[TBL] [Abstract][Full Text] [Related]
50. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection.
Passot G; Denbo JW; Yamashita S; Kopetz SE; Chun YS; Maru D; Overman MJ; Brudvik KW; Conrad C; Aloia TA; Vauthey JN
Surgery; 2017 Feb; 161(2):332-340. PubMed ID: 27592215
[TBL] [Abstract][Full Text] [Related]
51. The interplay of KRAS mutational status with tumor laterality in non-metastatic colorectal cancer: An international, multi-institutional study in patients with known KRAS, BRAF, and MSI status.
Kamphues C; Kadowaki S; Amini N; van den Berg I; Wang J; Andreatos N; Sakamoto Y; Ogura T; Kakuta M; Pikouli A; Geka D; Daitoku N; Theochari M; Buettner S; Akiyama T; Antoniou E; Pikoulis E; Theodoropoulos G; Imai K; Ijzermans JNM; Margonis GA; Akagi K; Kreis ME
J Surg Oncol; 2021 Mar; 123(4):1005-1014. PubMed ID: 33368279
[TBL] [Abstract][Full Text] [Related]
52. RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases.
Brudvik KW; Mise Y; Chung MH; Chun YS; Kopetz SE; Passot G; Conrad C; Maru DM; Aloia TA; Vauthey JN
Ann Surg Oncol; 2016 Aug; 23(8):2635-43. PubMed ID: 27016292
[TBL] [Abstract][Full Text] [Related]
53. [Impact of primary tumor site on the prognosis in different stage colorectal cancer patients after radical resection].
Han J; Zhang X; Zhang AD; Zhou XL; Feng L; Wang JY; Wang GY
Zhonghua Wai Ke Za Zhi; 2018 Jan; 56(1):68-73. PubMed ID: 29325357
[No Abstract] [Full Text] [Related]
54. The ALPPS Approach for Colorectal Liver Metastases: Impact of KRAS Mutation Status in Survival.
Serenari M; Alvarez FA; Ardiles V; de Santibañes M; Pekolj J; de Santibañes E
Dig Surg; 2018; 35(4):303-310. PubMed ID: 29032374
[TBL] [Abstract][Full Text] [Related]
55. Association of genomic profiles and survival in early onset and screening-age colorectal cancer patients with liver metastases resected over 15 years.
Narayan RR; Aveson VG; Chou JF; Walch HS; Sanchez-Vega F; Santos Fernandes GD; Balachandran VP; D'Angelica MI; Drebin JA; Jarnagin WR; Wei AC; Cercek A; Gönen M; Schultz N; Kingham TP
J Surg Oncol; 2022 Apr; 125(5):880-888. PubMed ID: 35066881
[TBL] [Abstract][Full Text] [Related]
56. The prognostic significance of clinicopathological characteristics in early-onset versus late-onset colorectal cancer liver metastases.
Li YT; Wang XY; Zhang B; Tao BR; Chen ZM; Ma XC; Han JH; Zhang C; Zhang R; Chen JH
Int J Colorectal Dis; 2023 Jan; 38(1):19. PubMed ID: 36658235
[TBL] [Abstract][Full Text] [Related]
57. Parenchymal-sparing hepatectomy for colorectal liver metastases reduces postoperative morbidity while maintaining equivalent oncologic outcomes compared to non-parenchymal-sparing resection.
Andreou A; Gloor S; Inglin J; Di Pietro Martinelli C; Banz V; Lachenmayer A; Kim-Fuchs C; Candinas D; Beldi G
Surg Oncol; 2021 Sep; 38():101631. PubMed ID: 34298267
[TBL] [Abstract][Full Text] [Related]
58. Conditional Survival After Hepatectomy for Colorectal Liver Metastasis: Results from the Colorectal Liver Operative Metastasis International Collaborative (COLOMIC).
Valenzuela CD; Moaven O; Solsky IB; Stauffer JA; Del Piccolo NR; Cheung T; Corvera CU; Wisneski AD; Cha CH; Pourhabibi Zarandi N; Dourado J; Perry KC; Russell G; Shen P
Ann Surg Oncol; 2023 Jun; 30(6):3413-3422. PubMed ID: 36859704
[TBL] [Abstract][Full Text] [Related]
59. Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.
Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M
Clin Colorectal Cancer; 2018 Sep; 17(3):170-178.e3. PubMed ID: 29627309
[TBL] [Abstract][Full Text] [Related]
60. Limited Prognostic Value of KRAS in Patients Undergoing Hepatectomy for Colorectal Liver Metastases.
Takeda Y; Mise Y; Takahashi Y; Ito H; Inoue Y; Yoshioka R; Ono Y; Saiura A
Ann Surg Oncol; 2022 Apr; 29(4):2383-2391. PubMed ID: 34851437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
